Reilly Financial Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Reilly Financial Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-200	Closed	-$1K	–	922
2016 Q4	$1K	Hold	200	–	–	﹤0.01%	788
2016 Q3	$1K	Hold	200	–	–	﹤0.01%	784
2016 Q2	$1K	Hold	200	–	–	﹤0.01%	751
2016 Q1	$1K	Hold	200	–	–	﹤0.01%	1111
2015 Q4	$2K	Hold	200	–	–	﹤0.01%	1062
2015 Q3	$2K	Hold	200	–	–	﹤0.01%	1127
2015 Q2	$3K	Hold	200	–	–	﹤0.01%	1159
2015 Q1	$2K	Buy	+200	New	+$2.07K	﹤0.01%	1162

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Reilly Financial Advisors's BCRX Position: Q1 2017 in Review

Reilly Financial Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2017, closing a stake of 200 shares — an estimated $1K sold.

Reilly Financial Advisors first reported a position in BCRX in Q1 2015 and held it in 8 quarters. The position peaked at $3K in Q2 2015. 117 funds tracked by Wall St. Rank hold BCRX as of Q1 2017.

Reilly Financial Advisors reported no remaining BioCryst Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Reilly Financial Advisors sold 200 BioCryst Pharmaceuticals shares in Q1 2017, an estimated $1K.
Reilly Financial Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2015 and held it in 8 quarters.
Reilly Financial Advisors's BioCryst Pharmaceuticals position peaked at $3K in Q2 2015.
117 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.